BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will est ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
Investors in BioNTech faced a one-two punch of negative developments, sending the company's stock tumbling approximately 19% to a fresh 52-week low. The double blow consisted of a disappointing ...
Investor attention is firmly fixed on BioNTech SE as it prepares to release its full-year and fourth-quarter 2025 financial results on March 10, 2026. The company's shares are currently navigating ...
Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA ...
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1, and mRNA ...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate ...
(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer ...
BioNTech and Bristol Myers Squibb have announced a partnership for the global co-development and co-commercialization of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, which aims to improve ...
Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific ...
Net Profit / (Loss) (190.4) 1,672.0 311.8 5,370.8 Outlook for the 2023 Financial YearThe Company reiterates its COVID-19 vaccine revenue guidance and updates its previous expense and capex guidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results